German biotech Fresenius Kabi has struck back at Samsung Bioepis’s latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.
Subscribe for instant access to all Lawyerly content.
